Study S000533

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06948422
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 974
Start: 2025-04-30
Primary completion: 2027-09
Lead sponsor: Eli Lilly and Company
Conditions: Hypertension
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZPL; OTHER:J2A-MC-GZL1; OTHER:J2A-MC-GZL2

Registered primary outcomes

Number of Participants Allocated to Each ISA [Week -8 to Week 0]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003621	Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension. Laffin L, American journal of preventive cardiology	2026	Protocol	PMID 42830762 DOI	cites ClinicalTrials.gov:NCT06948422; registry reference DERIVED:42830762